Kenneth M. Bate's most recent trade in Madrigal Pharmaceuticals Inc was a trade of 10,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Nov. 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 10,000 | 18,097 (0%) | 0% | 303.8 | 3,037,900 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 5,470 | 8,097 (0%) | 0% | 9.5 | 51,692 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 5,470 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 3,259 | 14,180 (0%) | 0% | 481.1 | 1,567,995 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 2,775 | 4,286 (0%) | 0% | 487.5 | 1,352,796 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 2,069 | 10,827 (0%) | 0% | 483.4 | 1,000,170 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,931 | 8,896 (0%) | 0% | 484.8 | 936,105 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,763 | 17,439 (0%) | 0% | 480.2 | 846,663 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,284 | 12,896 (0%) | 0% | 482.4 | 619,417 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,105 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,105 | 19,202 (0%) | 0% | 280.0 | 309,444 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 1,008 | 7,888 (0%) | 0% | 485.5 | 489,421 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 933 | 2,657 (0%) | 0% | 489.9 | 457,119 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 827 | 7,061 (0%) | 0% | 486.7 | 402,530 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 696 | 3,590 (0%) | 0% | 489.1 | 340,409 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 05 Nov 2025 | 30 | 2,627 (0%) | 0% | 491.0 | 14,729 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 10,000 | 12,627 (0%) | 0% | 16.5 | 164,600 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 2,567 | 5,227 (0%) | 0% | 365.3 | 937,793 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 2,516 | 7,794 (0%) | 0% | 364.2 | 916,428 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 2,317 | 10,310 (0%) | 0% | 363.4 | 842,014 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 1,104 | 3,523 (0%) | 0% | 367.6 | 405,865 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 896 | 2,627 (0%) | 0% | 368.6 | 330,226 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Aug 2025 | 600 | 4,627 (0%) | 0% | 366.1 | 219,683 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 20 Jun 2025 | 1,290 | 1,290 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 20 Jun 2025 | 715 | 2,627 (0%) | 0% | 0 | Common Stock | ||
| Astria Therapeutics Inc | Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2025 | 26,550 | 26,550 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 9,470 | 17,382 (0%) | 0% | 65.1 | 616,118 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 9,470 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 8,545 | 12,529 (0%) | 0% | 355.1 | 3,034,150 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 6,000 | 7,912 (0%) | 0% | 111.1 | 666,360 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 4,530 | 21,912 (0%) | 0% | 9.5 | 42,809 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 4,530 | 5,470 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 3,548 | 4,152 (0%) | 0% | 358.3 | 1,271,359 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 2,791 | 9,738 (0%) | 0% | 356.5 | 995,016 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 2,038 | 7,700 (0%) | 0% | 357.3 | 728,109 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 2,024 | 2,128 (0%) | 0% | 359.2 | 727,042 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 500 | 21,312 (0%) | 0% | 352.0 | 175,995 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 238 | 21,074 (0%) | 0% | 353.8 | 84,213 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 216 | 1,912 (0%) | 0% | 360.1 | 77,774 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 27 Feb 2025 | 100 | 21,812 (0%) | 0% | 351.0 | 35,101 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 25 Jun 2024 | 1,105 | 1,105 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 25 Jun 2024 | 714 | 1,912 (0%) | 0% | 0 | Common Stock | ||
| Astria Therapeutics Inc | Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 11,212 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 11,212 | 12,410 (0%) | 0% | 105.1 | 1,178,157 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 10,000 | 11,198 (0%) | 0% | 9.5 | 94,500 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 10,000 | 21,198 (0%) | 0% | 100.5 | 1,004,500 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 7,411 | 8,366 (0%) | 0% | 256.5 | 1,900,850 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 7,048 | 4,145 (0%) | 0% | 244.3 | 1,721,630 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 6,698 | 15,777 (0%) | 0% | 255.6 | 1,712,119 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 2,790 | 5,576 (0%) | 0% | 257.3 | 717,940 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 2,104 | 3,472 (0%) | 0% | 258.2 | 543,339 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 2,080 | 2,065 (0%) | 0% | 245.0 | 509,527 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 1,277 | 11,212 | - | - | Stock Option (Right to Buy) | ||
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 1,277 | 22,475 (0%) | 0% | 105.1 | 134,187 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 1,217 | 11,193 (0%) | 0% | 243.3 | 296,075 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 841 | 2,431 (0%) | 0% | 262.2 | 220,493 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 700 | 1,472 (0%) | 0% | 265.4 | 185,749 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 567 | 1,498 (0%) | 0% | 246.2 | 139,597 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 274 | 1,198 (0%) | 0% | 266.9 | 73,132 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 200 | 3,272 (0%) | 0% | 259.1 | 51,826 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 193 | 1,205 (0%) | 0% | 248.5 | 47,958 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 143 | 2,288 (0%) | 0% | 263.1 | 37,621 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 116 | 2,172 (0%) | 0% | 264.7 | 30,709 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 100 | 1,398 (0%) | 0% | 246.9 | 24,688 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 01 Apr 2024 | 7 | 1,198 (0%) | 0% | 249 | 1,743 | Common Stock | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 15 Jun 2023 | 1,198 | 1,198 (0%) | 0% | 0 | Common Stock | ||
| Astria Therapeutics Inc | Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2023 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| Madrigal Pharma Inc | Kenneth M. Bate | Director | 16 Jun 2022 | 9,470 | 9,470 | - | - | Stock Option (Right to Buy) | ||
| Astria Therapeutics Inc | Kenneth M. Bate | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,333 | 8,333 | - | - | Stock Option (right to buy) |